Thomas Jouary

机构：Centre Hospitalier De Pau · ORCID：0000-0002-9080-3661

发表论文 184 篇 · 总被引 16820 次 · h-index 39

代表论文

• Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial (2021 · The Lancet Oncology · 被引 391)
• Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial (2021 · The Lancet Oncology · 被引 74)
• Sweat Gland Tumors Arising on Acral Sites (2023 · The American Journal of Surgical Pathology · 被引 40)
• Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC) (2023 · Cancers · 被引 31)
• Porocarcinomas with PAK1/2/3 fusions: a series of 12 cases (2024 · Histopathology · 被引 28)
• Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial (2022 · European Journal of Cancer · 被引 24)